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The additional mean cost of pemetrexed plus cisplatin therapy,
over cisplatin monotherapy, was A$14,032.78 per patient. The
mean and median survival gain with pemetrexed plus cisplatin
therapy was found to be 0.191 and 0.233 years, respectively, rel-
ative to cisplatin monotherapy, over the 27-month period of
observation. The cost per life-year saved was A$73,470.04 for
mean and A$60,226.52 for median incremental survival. CON-
CLUSION: This survival beneﬁt is a highly patient-relevant
outcome. This economic evaluation found that pemetrexed plus
cisplatin therapy offers an acceptable cost-effectiveness ratio for
a small population of MPM patients in Australia.
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OBJECTIVES: The FDA’s approval of Avastin, Erbitux and other
novel agents has generated debate about the high cost and rela-
tive value of new cancer treatments. We sought to understand
whether oncologists consider the therapies they employ to be
cost-effective and to ascertain oncologists’ cost-effectiveness
thresholds for such therapies. METHODS: We surveyed 139
oncologists at two large academic hospitals in Boston. We asked
respondents to provide estimates for the cost and effectiveness
of Avastin (without appealing to published data) and whether
they thought the treatment offered “good value.” We also asked
respondents to judge how large a gain in life-expectancy would
justify a hypothetical new cancer therapeutic that cost $70,000
per year more than standard care. We used this information to
calculate implied cost-effectiveness thresholds (in QALYs) for
each respondent. Finally, we asked respondents about the role of
cost in their treatment recommendations. RESULTS: Ninety
oncologists (65%) completed the survey. Cost-effectiveness
thresholds, derived from the hypothetical scenario, averaged
over $300,000/QALY. Oncologists’ estimates of the cost and sur-
vival beneﬁt of Avastin implied a cost-effectiveness ratio in the
same range, yet only 25% of oncologists believed Avastin offered
good value. Oncologists who indicated a greater sensitivity to
costs in their prescribing behavior had signiﬁcantly lower cost-
effectiveness thresholds. CONCLUSIONS: Oncologists in an
academic medical setting had implied cost-effectiveness thresh-
olds that were roughly 6 times higher than a commonly cited
standard in the U.S. of $50,000/QALY. When asked about spe-
ciﬁc scenarios, however, oncologists implied that very small gains
in life expectancy were not worth the additional costs. Further,
most oncologists were dubious about whether a recently
approved therapy offered “good value.” As expensive new
cancer therapies enter clinical practice, oncologists’ views about
their role as practitioners may increasingly conﬂict with their
beliefs about the value offered by these therapies.
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OBJECTIVES: To encourage early adoption, Medicare pays a
temporary premium for selected new technologies (which are
called pass-through technologies) in the outpatient setting.
Implicit decisions are being made that the additional money
spent for these pass-through technologies is worthwhile to the
Medicare program. The goal of this study was to examine how
implicit decisions being made for pass-through technologies
compare with explicit cost-effectiveness criteria. METHODS:
We selected as case studies four technologies—two pass-through
devices (embolic capture devices and silicone oil for retinal tam-
ponade) and two pass-through drugs/biologicals (pegﬁlgrastim,
triptorelin pamoate)—that Medicare estimates will account for
the bulk of pass-through spending for 2004. We examined
whether cost-effectiveness literature existed at the time of pass-
through approval and critically examined its quality. We then
used publicly-available data (e.g., Medicare claims and payment
rates) to supplement available studies and examine cost-
effectiveness thresholds from Medicare’s perspective. RESULTS:
Cost-effectiveness studies were available for two of the four case
study technologies at the time of their application review. The
quality was variable. These studies, later publications, and our
own analyses suggest some case study technologies could be cost-
effective in at least a subset of the Medicare population in which
they are used. CONCLUSIONS: Cost-effectiveness information
is sometimes available early in the life cycle of a technology and
may provide additional useful information about whether and
for which subpopulation Medicare should pay a premium for a
new technology. Policy analysts must evaluate cost-effectiveness
information critically, however, and may need to conduct sup-
plemental analyses as a result. Medicare payment decisions do
not now reﬂect any judgment about the value of that technology
in terms of clinical beneﬁt for incremental cost. The challenge to
Medicare is to be able to limit pass-through payments to only
those populations for whom there is proven value.
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OBJECTIVES: To critically evaluate published cost-effectiveness
(CE) models and identify model elements contributing to the
large variability in results. METHODS: A literature search of
MEDLINE and EMBASE from 1985–2004 identiﬁed eight
English-language CE models comparing coxibs to a nonsteroidal
anti-inﬂammatory drug (NSAID)-alone regimen. Two studies
were excluded due to unavailable model input data. Model time
horizons ranged from six months to lifetime, and primary out-
comes ranged from gastrointestinal (GI) events averted to life-
years gained and quality-adjusted life-years gained. Common
elements across models were minor GI discomfort/dyspepsia,
moderate GI events/symptomatic ulcer, and severe GI events.
Only two of the analyses included cardiovascular side effects. To
compare model inputs we standardized all analyses to a six-
month tree structure with the three GI side effects. Study prob-
abilities were converted to six-month rates where necessary 
and costs were converted to $US using the purchasing power
parity index. Cost offsets between coxibs and NSAIDs were cal-
culated by multiplying the probability of the GI event by cost
per event. RESULTS: The relative price used for coxibs com-
pared with NSAIDs differed widely across studies (median over
six months, $156; range, $14–$387). Differences in total GI
event cost offsets were small (median, -$41; range -$53 to 
-$18). Moderate GI events provided the greatest GI event cost
